Lantheus Holdings, Inc.LNTHEarnings & Financial Report
Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.
Revenue
$378.7M
Gross Profit
$242.1M
Operating Profit
$133.7M
Net Profit
$131.1M
Gross Margin
63.9%
Operating Margin
35.3%
Net Margin
34.6%
YoY Growth
18.4%
EPS
$1.79
Lantheus Holdings, Inc. Q3 FY2024 Financial Summary
Lantheus Holdings, Inc. reported revenue of $378.7M (up 18.4% YoY) for Q3 FY2024, with a net profit of $131.1M (down 0.7% YoY) (34.6% margin). Cost of goods sold was $136.6M, operating expenses totaled $108.4M.
Key Financial Metrics
| Total Revenue | $378.7M |
|---|---|
| Net Profit | $131.1M |
| Gross Margin | 63.9% |
| Operating Margin | 35.3% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Lantheus Holdings, Inc. Q3 FY2024 revenue of $378.7M breaks down across 5 segments, led by Radiopharmaceutical Oncology at $259.8M (68.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Radiopharmaceutical Oncology | $259.8M | 68.6% |
| Definity | $77.0M | 20.3% |
| Techne Lite | $20.5M | 5.4% |
| Strategic Partnerships And Other | $15.3M | 4.0% |
| Other Precision Diagnostics | $6.3M | 1.7% |
Lantheus Holdings, Inc. Revenue by Segment — Quarterly Trend
Lantheus Holdings, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Radiopharmaceutical Oncology and Definity) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Radiopharmaceutical Oncology | $240.2M | $240.6M | $250.6M | $257.7M |
| Definity | $85.3M | $81.8M | $83.9M | $79.2M |
| Techne Lite | $21.0M | $21.1M | $25.0M | $19.7M |
| Strategic Partnerships And Other | $23.3M | $13.7M | $11.6M | $10.7M |
| Other Precision Diagnostics | $5.9M | — | $6.9M | — |
Lantheus Holdings, Inc. Annual Revenue by Year
Lantheus Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.5B |
| 2024 | $1.5B |
| 2023 | $1.3B |
| 2022 | $935.1M |
Lantheus Holdings, Inc. Quarterly Revenue & Net Profit History
Lantheus Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $406.8M | +4.0% | $54.1M | 13.3% |
| Q3 FY2025 | $384.0M | +1.4% | $27.8M | 7.2% |
| Q2 FY2025 | $378.0M | -4.1% | $78.8M | 20.8% |
| Q1 FY2025 | $372.8M | +0.8% | $72.9M | 19.6% |
| Q4 FY2024 | $391.1M | +10.5% | $-11.8M | -3.0% |
| Q3 FY2024 | $378.7M | +18.4% | $131.1M | 34.6% |
| Q2 FY2024 | $394.1M | +22.5% | $62.1M | 15.8% |
| Q1 FY2024 | $370.0M | +23.0% | $131.1M | 35.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $370.0M | $394.1M | $378.7M | $391.1M | $372.8M | $378.0M | $384.0M | $406.8M |
| YoY Growth | 23.0% | 22.5% | 18.4% | 10.5% | 0.8% | -4.1% | 1.4% | 4.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.83B | $1.94B | $2.05B | $1.98B | $2.06B | $2.12B | $2.28B | $2.23B |
| Liabilities | $885.8M | $913.1M | $869.9M | $892.3M | $891.0M | $949.3M | $1.16B | $1.14B |
| Equity | $945.5M | $1.03B | $1.18B | $1.09B | $1.16B | $1.17B | $1.12B | $1.09B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $127.2M | $84.7M | $175.1M | $157.7M | $107.6M | $87.1M | $105.3M | $90.2M |